From the above discussion, it is revealed that these high‐risk factors for AAA are correlated with upregulation of ACE/Ang II/AT1R axis and downregulation of ACE2/Ang‐(1–7)/MasR axis, suggesting that both axes may be therapeutic AAA targets. The gene discussed is MAS1L; the disease is triple-A syndrome.